Navigation Links
Steroids May Be Overrated in Treatment of COPD

But experts disagree over whether to continue using them or not,,

THURSDAY, Feb. 4 (HealthDay News) -- Patients suffering from chronic obstructive pulmonary disease (COPD) are often given inhaled corticosteroids to help ease exacerbations of the disease, but a new study finds these drugs may be of only limited benefit.

While inhaled corticosteroids have been widely prescribed to help treat the symptoms of COPD, they have also been linked to an increased risk of pneumonia, the researchers note.

"I think the study is important and shows that the benefits of addition of inhaled corticosteroids to long-acting beta agonist formulations are only minimal compared to significant risks of pneumonia," said Dr. Sonal Singh, an assistant professor of medicine at Johns Hopkins University, who was not involved in the study.

"Unfortunately, therapeutic options for patients with COPD are limited and carry their own risks such as cardiovascular risks with anticholinergics," he added. "Thus a regulatory reassessment of the safety of COPD inhalers is needed."

COPD is an incurable condition that progressively destroys the lungs. While there is no cure, various medications can help treat the symptoms, including inhaled corticosteroids, long-acting beta agonists such as Serevent, short-acting beta agonists such as albuterol, and anticholinergics such as Spiriva.

Singh noted that while inhaled corticosteroids don't seem to add much to the treatment of COPD, long-acting beta agonists are not approved for use without them. "It's a real catch-22. It's not clear that there are any benefits and we know that the harms are substantial," Singh said.

"I sometimes use inhaled corticosteroids, but it's becoming less and less," he added.

The report is published in the February issue of the journal Chest.

For the study, Dr. Ritesh Agarwal and colleagues from the department of pulmonary medicine at the Postgraduate Institute of Medical Education and Research in Chandigarh, India, looked at 11 studies that compared inhaled corticosteroids with placebos in some 8,164 COPD patients.

The researchers found that these drugs only had a modest effect in reducing the number of exacerbations. In fact, even this small benefit was limited to patients who had lost more than 50 percent of their lung function.

Yet, further analysis of the data found that even 50 percent of lung function was not a predictor of the ability of inhaled corticosteroids to reduce the number of exacerbations, Agarwal's team found.

Given these findings, the researchers say that "the role of inhaled corticosteroids in preventing COPD exacerbations needs reappraisal."

However, Dr. Neil Schachter, a professor of pulmonary medicine at Mount Sinai Medical Center in New York City, isn't ready to give up on inhaled corticosteroids.

"There does appear to be an improvement in terms of the rate of exacerbations of patients with COPD who take drugs that contain corticosteroids," he said. "That confirms what most people believe, that if you treat COPD with most of the drugs we use to treat it, you can reduce and delay the onset of exacerbations."

Schachter treats most of his COPD patients with a combination of drugs. Many patients take inhaled corticosteroids, long-acting beta agonists and the anticholinergic Spiriva. He said the effects of these drugs are additive, making for a more powerful treatment than using a single drug.

"My bias is to use everything," he said. "My impression is that these patients do better on triple therapy. They have better lives, less symptoms, fewer exacerbations and they probably live a bit longer."

Another report in the same issue of the journal found that COPD patients have a high rate of depression. In this study, a research team led by Christoph R. Meier, from University Basel in Switzerland, collected data on 35,722 COPD patients and 35,722 healthy people.

The researchers found among those with COPD, 23.1 percent were diagnosed with depression, compared with 16.8 percent of people without COPD. Moreover, those with the most severe COPD had the greatest risk of developing depression.

More information

For more information on COPD, visit the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Sonal Singh, M.D., M.P.H., assistant professor, medicine, Johns Hopkins University, Baltimore; Neil Schachter, M.D., professor, pulmonary medicine, Mount Sinai Medical Center, New York City; February 2010, Chest

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Steroids Seem Safe for Babies at Risk of Early Birth
2. Batters may achieve dramatic increases in home runs through steroids
3. Repeat steroids to premature infants linked to cerebral palsy
4. International Law Enforcement Operation Targets Underground Manufacture of Anabolic Steroids
5. Steroids Are Abused for Skin, Not Just Muscles
6. Research Indicates Nearly 25 Percent of Supplements Are Contaminated With Steroids, Stimulants and Banned Substances
7. ENDO 08: Latest news on hormones, steroids, obesity, diabetes and more
8. Corticosteroids of Little Use Against Childhood Meningitis
9. Kids at Risk: Report Identifies 150 Websites Selling Anabolic Steroids
10. Changes in sex steroids associated with menopause
11. Steroids aid recovery from pneumonia, UT Southwestern researchers say
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: